Table 6.
Mean and standard deviation of MG-ADL and QMG scores in Generalized signs at the beginning and at the end of each cycle of therapy with Efgartigimod.
| Generalized signs in MG-ADL assessment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | |||||||||
| MG-ADL | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 3.20 | 1.90 | 3.40 | 2.20 | 5.25 | 3.00 | 0.03 | 0.07 | 0.11 | 0.10 | 0.45 |
| SD | 1.44 | 1.73 | 2.11 | 1.89 | 2.30 | 2.07 | |||||
| Generalized signs in QMG assessment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | |||||||||
| QMG | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 9.22 | 7.89 | 9.11 | 7.22 | 9.66 | 9.50 | 0.065 | 0.016 | 0.89 | 0.020 | 0.87 |
| SD | 2.54 | 3.55 | 5.28 | 3.99 | 3.80 | 4.70 | |||||
* Repeated measures ANOVA with Post Hoc analysis using Bonferron method.